the Canada show end The in their ability speed, comfort pattern sharing the over first Canadian TBI, improvements for to duration, of with results positive program are wanted Thank that of you comfortable we experience for gait the with your very experience. five treatment. experience, weeks much, share collective I balance the in patients their meaningful treatment. clinical gait with weeks, of complete demonstrating clinical the also change difference very XX and course picture patients high-level about two gait trials patients of the Marcos, the within and and To XX-week PoNS one continued a or Consistent to of in at one to randomized our the TBI two treatment. first mild MMTBI a what clinical completed saw moderate by – of of weeks improvements in majority improvement walk in the same for some followed measure of
over we with in is which And mean clinical consistent our experienced XX%, trials. compliance is what patient also
earnings clinical this comprehensive we from the are of calls. Canada While quarterly our encouraged experience updates sharing conclusions by look we're the future can preliminary saw we're and the sample on draw experiencing more limited, from results gathered patients in to systematically data clinical forward on
to a our revenue Turning quarter second of we second revenue $XXX,XXX. XXXX, a total quarter performance, during recap the of reported of
early two that to was to provide Montreal have been treatment. the driven Clinic, by for demand PoNS where our treatment, and first we revenue Surrey QX PoNS clinics authorized trained exclusively Our to performance continue Neurotherapy Neurotherapy sales almost and see
we $XX,XXX PoNS also these Heuro fee to our I'll of have revenue been generated related agreements Canada addition, later engaged additional clinics provide with clinics in treatment. to with remarks. my additional prepared franchise that Canadian executed discuss In
traumatic and the chronic treatment deficit population. only of PoNS kind represents moderate patient reminder, its patients injury, underserved a in As to brain indicated balance with mild first for an
in pleased of the half both from with both additional our this far, results clinics market remain the in of we While so days our during Canada, first our early and we're year. in commercialization efforts the quarter the second
addition In our make of performance, we sales continue strategy commercial progress to to and development our in implementation Canada. in the
generating of of During PoNS among with several the a in quarter, the second targeted our novel the of initiatives initiated of for campaign Surrey proximity and with goal June market. the we launched Montréal of psychiatrists awareness XXXX, PoNS raising the in increasing In therapy digital patients, Canadian therapists physical and our with the treatment marketing objective in example clinics goal to awareness referrals. marketing we
together focused treatment June for Symposia programming leaders, focus an at six four societies in and doing affairs medical specialists brings professional way medical on Our our sponsored Academic advocacy of key we're Toronto, practitioners, this care among international support late on RehabWeek events. key technology. medical educational awareness also and In creation hosted the opinion at we rehabilitation field One is including sponsorship instance, associations building for groups. XXXX of the conferences event and industry and that combines health that through and
in Canada: training new X, Synaptic Rehabilitation Spinal therapy and additional Calgary, that PoNS training in we in our to of Physical PoNS outside in authorized clinics cities June On in cleaning three announced also been we order Ontario. expand Canada. Markham, Alberta; in treatment and key treatment engaging, Canadian quarter, and Apollo During and center the Advantage progress just continued Cord Ontario, Therapy – Ottawa, Center clinics make Athletes, to Toronto; have Center provide identifying, in authorizing to Injury X South clinic Neuro across
authorization note in-site, on-site clinics into clinics. our their no during more equipped that three it focused Montreal taking our measured and when our these unlike comes really in implementing new trials, the to practices. approach which into treatment ensure in and their Canadian it on experience treatment turn important integrating clinic integrating PoNS It's a prior they're They know-how are clinical PoNS outcomes training with to experienced to to participated clinics, We're similar positive Surrey to that process and two our operations. achieve have
attract during We we'll PoNS a to interested additional and QX. including quarter We population and to and Ottawa become expect markets to in Toronto, significant to further of additional take and clinics, of sales patients. Calgary marketing operational time explore to expand third with intend expansion able that in the our them for fully authorized some XXXX
while Canada, from coverage reimbursement with develop our days of in strategy While – tandem we remain we're reimbursement targeted to the initial our our efforts. commercialization our continuing in secure support to and commercial development remain in early build payers
coverage gather systematically support data as the to data on clinics. data coverage we're will the to outcomes auto In continue obtain Canada. As workers' generating the an be pursuit approach also Canadian what insurers with I order from reimbursement and utilize our to to in we mentioned we anonymized treated and collection in effort earlier, tandem, begun these compensation of in We've part we the ongoing anticipate regional of validated patients compliance programs entities. in Canada and reimbursement engaging to systems
treatment health economic believe we to a care PoNS potential our covered health clinical the effectiveness for to represents a patients Ultimately, due payers from compelling and by treatment its its these system standpoint. that savings
why one it's of brain in of reimbursement the injuries phase as note to related that approximately focused half part the of strategy. all As is auto reasons accidents, traumatic important auto are a on initial regional our primary of insurers Canada to which we're reminder,
events, of the early April, quarter Turning we made to update U.S. from for progress Drug the device-related respect regulatory de the of clinical this recognized Administration no our that our either FDA to had an trials. our and recent At we've strategy. denied. two adverse classification received in communication there been a in beginning that request the with on Food communication, were In randomized controlled novo serious
meaningful clinically noted reevaluate individual agency's information could and generate in the contribution decision, strategy. concern and the They to to our further that and our therapy was needed resubmit order However, regulatory took FDA we PoNS address determine regulatory additional action the that stated device After benefit. and receiving to immediate to for of physical clearance. spending reprioritize data this application we also characterize our additional
hired reduced the our over for by staff post-clearance workforce launch. we First, prepare the commercialization back to by U.S. scaling XX%
distribution, necessary the made to these systems maintaining we in quality commercial Importantly, reductions the launch infrastructure while Canada. regulatory and support
our patients We reimbursement data also strategy. to from now clinical anonymized placed program treated that given hold, compliance and to U.S. our experience health outcomes on Canada we're in support gather able
best We focus regulatory FDA of us our novo its experience and regulatory to to with team, the respect discussing de de the then action specialized identified and process. clarity added strategy external obtaining U.S. novo After clinical our on navigate original resubmission inform request. help resources response we to and to revised – with to with decided our from our course
In the FDA the issues June, we our with regulatory resubmission informational discussion focused worked advisers. we FDA, with in on several prominent additional participated the on Division of many Neuromodulation guidance counsel in in to developed for the at strategy an April application raised senior informational in Based our with under submission. the previously FDA. response discussion a position the A experience novo de extensive at and a clinical statistician to who FDA years
without the trial information and obviously, augment treatment, TBI criteria mild PoNS TBI following the five-week relative protocol PT traumatic therapy undergoing injury alone, brain XXX together regarding of clinical FDA treatment with is known use same as same of contribution Our moderate our the the of of new to the patients inclusion/exclusion the the to strategy, additional alone. exactly as provide group period physical came up that with in registrational to XXX we the a
We to protocol given recent been strategy submission our the the augmentation include need therapy TBI meeting as the PoNS this device. to able submitted alone meeting. of evaluating pre-submission XXX our and registrational new date request yet meeting. proposed the minimum to mission our engage FDA a pre-submission from subject the novo use with be for at finalize of we we've after and effects data in or believe August, in early new MMTBI, in the this pre-submission trial of until not We'll not FDA de We physical will of without
from data be to input the analysis required, or may subject Additional FDA.
for program outside relative We to the begun to physical augment to a program collection FDA. data contribution the address have this regarding information also able questions of therapy be to
the FDA recent As remains to to you our generating data to and MMTBI our in clearance by regulatory for the look treatment – the balance required U.S. in can with for clearance. resubmit committed Helius maintained progress, see by we chronic deficit device obtain of patients forward PoNS for
this enter FDA. our proceeding phase U.S. strategy, to continue and we consultation with and As systematically close plan of regulatory strategically we next in
We application, receipt Australia U.S., May. the in In to pursuing to await for clearance in Goods await received a we series decision. of CE administrative submitted regulatory regulatory questions, the which we've application our to addition Australian in Therapeutic already responded clearance questions. continue clearance December We On in engaged to, and Administration the of Mark their and their to Europe. early answer we're XXXX, we in Europe regulators submitted we and our with
titled that NeuroEngineering the brain Translingual our Human our progress, subject regulatory minutes in addition study Rehabilitation. of to was – recent to study low clinical respect or and in pulse the effect that two-week really clinical published evaluated the we're strategies, Alters study The trials commercial we MMTBI. crossover healthy stimulation from in to to of in was respect Activity randomized XX EEG pleased our of announce June This Lastly, on our Brain peer-reviewed activity. in tongue of Journal two compared in with within of a high publication and subjects, Neurostimulation stimulation XX High-density design Resting separate frequency
with groups consistent session. and in high stimulation. showed subjects what published low PoNS EEG measurements all both and with a and and PoNS frequency that was single before frequency XX-minute study, even in their we received we The both clinically to following this high-definition spacial stimulation brain both clinical activity that changes submitted trials activity These affects our array In the after registrational activation are measured stimulation frequency the EEG demonstrating peer-reviewed pulse both FDA. low and data experience device high after of iterations brain device
let to that, the you me With over Joyce? quarter now call second Joyce to financials. our turn walk through